Education
About Us
Working with TipRanks
Follow Us
Upstream Bio, Inc. (UPB)
NASDAQ:UPB
UPB Stock Chart & Stats
$30.30
$0.36(1.20%)
At close: 4:00 PM EST
$30.30
$0.36(1.20%)
Day’s Range― - ―
52-Week Range$5.14 - $33.68
Previous CloseN/A
Volume30.66K
Average Volume (3M)388.50K
Market Cap
$1.42B
Enterprise Value$1.35B
Total Cash (Recent Filing)$372.43M
Total Debt (Recent Filing)$1.42M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Mar 18, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding54,038,590
10 Day Avg. Volume473,530
30 Day Avg. Volume388,499
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.80
Price to Sales (P/S)356.14
P/FCF Ratio-14.14
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue480.55
Enterprise Value/Gross Profit485.93
Enterprise Value/Ebitda-9.87
Forecast
1Y Price Target
$48.80Price Target Upside61.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Therapeutic ExposurePharmacokinetic and pharmacodynamic modeling indicates sustained drug concentrations across extended dosing intervals, which supports the potential for comparable or improved reductions in asthma exacerbations versus competing therapies.
Extended Dosing ConvenienceVerekitug's potential to deliver clinically meaningful efficacy with just two to four annual doses could appeal to patients and clinicians seeking lower treatment burden, supporting faster commercial uptake.
Trial Design And Readout PotentialA well-powered VALIANT trial combined with strong Phase I biomarker signals increases the likelihood of a positive Phase II readout that could de-risk Phase III planning and strengthen investor confidence.
Bears Say
Cash Runway And Financing RiskRelatively high cash burn and a limited cash runway noted by an analyst could force additional fundraising, which may dilute shareholders or divert management focus from clinical and commercial execution.
High Commercial Efficacy Threshold And Switching InertiaAsthma patients show low switching between biologic classes and a new therapy generally needs around a forty-five percent reduction in exacerbations to be seen as commercially viable, raising the bar for market entry.
Variable Efficacy Across Patient SubgroupsSecondary endpoints such as symptom scores and lung function are expected to improve mainly in T2-high patients, creating uncertainty about consistent benefit across the broader asthma population.
Upstream Bio, Inc. News
UPB FAQ
What was Upstream Bio, Inc.’s price range in the past 12 months?
Upstream Bio, Inc. lowest stock price was $5.14 and its highest was $33.68 in the past 12 months.
What is Upstream Bio, Inc.’s market cap?
Upstream Bio, Inc.’s market cap is $1.42B.
When is Upstream Bio, Inc.’s upcoming earnings report date?
Upstream Bio, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 37 days.
How were Upstream Bio, Inc.’s earnings last quarter?
Upstream Bio, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.782 by $0.152.
Is Upstream Bio, Inc. overvalued?
According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued.
Does Upstream Bio, Inc. pay dividends?
Upstream Bio, Inc. does not currently pay dividends.
What is Upstream Bio, Inc.’s EPS estimate?
Upstream Bio, Inc.’s EPS estimate is -0.7.
How many shares outstanding does Upstream Bio, Inc. have?
Upstream Bio, Inc. has 54,038,590 shares outstanding.
What happened to Upstream Bio, Inc.’s price movement after its last earnings report?
Upstream Bio, Inc. reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.782. Following the earnings report the stock price went down -1.293%.
Which hedge fund is a major shareholder of Upstream Bio, Inc.?
Currently, no hedge funds are holding shares in UPB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Upstream Bio, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.80 (61.06% Upside)
$48.80 (61.06% Upside)
Hedge Fund Trend
Decreased
By 636.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.21%
12-Months-Change
Fundamentals
Return on Equity
-40.80%
Trailing 12-Months
Asset Growth
68.11%
Trailing 12-Months
Company Description
Upstream Bio, Inc.
Upstream Bio, Inc. (UPB) is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company operates primarily in the biopharmaceutical sector, specializing in the research and development of novel treatments for various diseases, particularly in the fields of oncology and autoimmune disorders. Upstream Bio aims to leverage its proprietary technology platform to advance its pipeline of drug candidates, ultimately seeking to improve patient outcomes through targeted therapies.
UPB Stock 12 Month Forecast
Average Price Target
$48.80
▲(61.06% Upside)
Technical Analysis
Theravance Biopharma
―
Bicycle Therapeutics
―
Prime Medicine, Inc.
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Ownership Overview
8.76% Insiders
18.86% Mutual Funds
46.70% Other Institutional Investors
16.47% Public Companies and
Individual Investors